Acute Intermittent Porphyria Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Diagnosis ( Blood Test, Serum Test, Urine Test, DNA Test, Others ); Treatment ( Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Others ); End-User ( Hospitals, Clinics, Research Centers, Others )

Code: RW00013874169
The Insight Partners
Feb-2021
Life Sciences
150 Pages

MARKET INTRODUCTION
Acute intermittent porphyria (AIP) is a rare metabolic disorder that is characterized by partial deficiency of the enzyme hydroxymethylbilane synthase (also known as porphobilinogen deaminase). This enzyme deficiency can result in the accumulation of porphyrin precursors in the body.
MARKET DYNAMICS
The acute intermittent porphyria market is driving due to expanding prevalence of rare diseases, developing interest for better treatment. However, less awareness among people could restrict the market growth in the next few years.
MARKET SCOPE
The "Acute Intermittent Porphyria Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of acute intermittent porphyria market with detailed market segmentation diagnosis, treatment, and end-user. and region. The acute intermittent porphyria market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in acute intermittent porphyria market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The acute intermittent porphyria market is segmented on the basis of diagnosis, treatment, and end-user. In terms of diagnosis, the global acute intermittent porphyria market can be classified into blood test, serum test, urine test, DNA test, and others. Based on treatment, the global acute intermittent porphyria market can be categorized into prophylactic hematin infusions, gonadotropin-releasing hormone analogues, and others. In terms of end-user, the market can be divided into hospitals, clinics, research centers, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Acute Intermittent Porphyria market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Acute Intermittent Porphyria market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Acute Intermittent Porphyria market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Acute Intermittent Porphyria market in these regions.
MARKET PLAYERS
The report covers key developments in the acute intermittent porphyria market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from acute intermittent porphyria market are anticipated to have lucrative growth opportunities in the future with the rising demand for acute intermittent porphyria market in the global market. Below mentioned is the list of few companies engaged in the acute intermittent porphyria market.
The report also includes the profiles of key players in acute intermittent porphyria market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Recordati Rare Diseases Inc.
- Lundbeck Inc.
- Alnylam Pharmaceuticals, Inc.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Acute Intermittent Porphyria Market - By Diagnosis
1.3.2 Acute Intermittent Porphyria Market - By Treatment
1.3.3 Acute Intermittent Porphyria Market - By End-User
1.3.4 Acute Intermittent Porphyria Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ACUTE INTERMITTENT PORPHYRIA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ACUTE INTERMITTENT PORPHYRIA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ACUTE INTERMITTENT PORPHYRIA MARKET - GLOBAL MARKET ANALYSIS
6.1. ACUTE INTERMITTENT PORPHYRIA - GLOBAL MARKET OVERVIEW
6.2. ACUTE INTERMITTENT PORPHYRIA - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ACUTE INTERMITTENT PORPHYRIA MARKET - REVENUE AND FORECASTS TO 2027 - DIAGNOSIS
7.1. OVERVIEW
7.2. DIAGNOSIS MARKET FORECASTS AND ANALYSIS
7.3. BLOOD TEST
7.3.1. Overview
7.3.2. Blood Test Market Forecast and Analysis
7.4. SERUM TEST
7.4.1. Overview
7.4.2. Serum Test Market Forecast and Analysis
7.5. URINE TEST
7.5.1. Overview
7.5.2. Urine Test Market Forecast and Analysis
7.6. DNA TEST
7.6.1. Overview
7.6.2. DNA Test Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. ACUTE INTERMITTENT PORPHYRIA MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT
8.1. OVERVIEW
8.2. TREATMENT MARKET FORECASTS AND ANALYSIS
8.3. PROPHYLACTIC HEMATIN INFUSIONS
8.3.1. Overview
8.3.2. Prophylactic Hematin Infusions Market Forecast and Analysis
8.4. GONADOTROPIN-RELEASING HORMONE ANALOGUES
8.4.1. Overview
8.4.2. Gonadotropin-Releasing Hormone Analogues Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ACUTE INTERMITTENT PORPHYRIA MARKET - REVENUE AND FORECASTS TO 2027 - END-USER
9.1. OVERVIEW
9.2. END-USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICS
9.4.1. Overview
9.4.2. Clinics Market Forecast and Analysis
9.5. RESEARCH CENTERS
9.5.1. Overview
9.5.2. Research Centers Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis
10. ACUTE INTERMITTENT PORPHYRIA MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Acute Intermittent Porphyria Market Overview
10.1.2 North America Acute Intermittent Porphyria Market Forecasts and Analysis
10.1.3 North America Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.1.4 North America Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.1.5 North America Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.1.6 North America Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.1.6.1 United States Acute Intermittent Porphyria Market
10.1.6.1.1 United States Acute Intermittent Porphyria Market by Diagnosis
10.1.6.1.2 United States Acute Intermittent Porphyria Market by Treatment
10.1.6.1.3 United States Acute Intermittent Porphyria Market by End-User
10.1.6.2 Canada Acute Intermittent Porphyria Market
10.1.6.2.1 Canada Acute Intermittent Porphyria Market by Diagnosis
10.1.6.2.2 Canada Acute Intermittent Porphyria Market by Treatment
10.1.6.2.3 Canada Acute Intermittent Porphyria Market by End-User
10.1.6.3 Mexico Acute Intermittent Porphyria Market
10.1.6.3.1 Mexico Acute Intermittent Porphyria Market by Diagnosis
10.1.6.3.2 Mexico Acute Intermittent Porphyria Market by Treatment
10.1.6.3.3 Mexico Acute Intermittent Porphyria Market by End-User
10.2. EUROPE
10.2.1 Europe Acute Intermittent Porphyria Market Overview
10.2.2 Europe Acute Intermittent Porphyria Market Forecasts and Analysis
10.2.3 Europe Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.2.4 Europe Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.2.5 Europe Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.2.6 Europe Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Acute Intermittent Porphyria Market
10.2.6.1.1 Germany Acute Intermittent Porphyria Market by Diagnosis
10.2.6.1.2 Germany Acute Intermittent Porphyria Market by Treatment
10.2.6.1.3 Germany Acute Intermittent Porphyria Market by End-User
10.2.6.2 France Acute Intermittent Porphyria Market
10.2.6.2.1 France Acute Intermittent Porphyria Market by Diagnosis
10.2.6.2.2 France Acute Intermittent Porphyria Market by Treatment
10.2.6.2.3 France Acute Intermittent Porphyria Market by End-User
10.2.6.3 Italy Acute Intermittent Porphyria Market
10.2.6.3.1 Italy Acute Intermittent Porphyria Market by Diagnosis
10.2.6.3.2 Italy Acute Intermittent Porphyria Market by Treatment
10.2.6.3.3 Italy Acute Intermittent Porphyria Market by End-User
10.2.6.4 Spain Acute Intermittent Porphyria Market
10.2.6.4.1 Spain Acute Intermittent Porphyria Market by Diagnosis
10.2.6.4.2 Spain Acute Intermittent Porphyria Market by Treatment
10.2.6.4.3 Spain Acute Intermittent Porphyria Market by End-User
10.2.6.5 United Kingdom Acute Intermittent Porphyria Market
10.2.6.5.1 United Kingdom Acute Intermittent Porphyria Market by Diagnosis
10.2.6.5.2 United Kingdom Acute Intermittent Porphyria Market by Treatment
10.2.6.5.3 United Kingdom Acute Intermittent Porphyria Market by End-User
10.2.6.6 Rest of Europe Acute Intermittent Porphyria Market
10.2.6.6.1 Rest of Europe Acute Intermittent Porphyria Market by Diagnosis
10.2.6.6.2 Rest of Europe Acute Intermittent Porphyria Market by Treatment
10.2.6.6.3 Rest of Europe Acute Intermittent Porphyria Market by End-User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Acute Intermittent Porphyria Market Overview
10.3.2 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis
10.3.3 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.3.4 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.3.5 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.3.6 Asia-Pacific Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Acute Intermittent Porphyria Market
10.3.6.1.1 Australia Acute Intermittent Porphyria Market by Diagnosis
10.3.6.1.2 Australia Acute Intermittent Porphyria Market by Treatment
10.3.6.1.3 Australia Acute Intermittent Porphyria Market by End-User
10.3.6.2 China Acute Intermittent Porphyria Market
10.3.6.2.1 China Acute Intermittent Porphyria Market by Diagnosis
10.3.6.2.2 China Acute Intermittent Porphyria Market by Treatment
10.3.6.2.3 China Acute Intermittent Porphyria Market by End-User
10.3.6.3 India Acute Intermittent Porphyria Market
10.3.6.3.1 India Acute Intermittent Porphyria Market by Diagnosis
10.3.6.3.2 India Acute Intermittent Porphyria Market by Treatment
10.3.6.3.3 India Acute Intermittent Porphyria Market by End-User
10.3.6.4 Japan Acute Intermittent Porphyria Market
10.3.6.4.1 Japan Acute Intermittent Porphyria Market by Diagnosis
10.3.6.4.2 Japan Acute Intermittent Porphyria Market by Treatment
10.3.6.4.3 Japan Acute Intermittent Porphyria Market by End-User
10.3.6.5 South Korea Acute Intermittent Porphyria Market
10.3.6.5.1 South Korea Acute Intermittent Porphyria Market by Diagnosis
10.3.6.5.2 South Korea Acute Intermittent Porphyria Market by Treatment
10.3.6.5.3 South Korea Acute Intermittent Porphyria Market by End-User
10.3.6.6 Rest of Asia-Pacific Acute Intermittent Porphyria Market
10.3.6.6.1 Rest of Asia-Pacific Acute Intermittent Porphyria Market by Diagnosis
10.3.6.6.2 Rest of Asia-Pacific Acute Intermittent Porphyria Market by Treatment
10.3.6.6.3 Rest of Asia-Pacific Acute Intermittent Porphyria Market by End-User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Acute Intermittent Porphyria Market Overview
10.4.2 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis
10.4.3 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.4.4 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.4.5 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.4.6 Middle East and Africa Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Acute Intermittent Porphyria Market
10.4.6.1.1 South Africa Acute Intermittent Porphyria Market by Diagnosis
10.4.6.1.2 South Africa Acute Intermittent Porphyria Market by Treatment
10.4.6.1.3 South Africa Acute Intermittent Porphyria Market by End-User
10.4.6.2 Saudi Arabia Acute Intermittent Porphyria Market
10.4.6.2.1 Saudi Arabia Acute Intermittent Porphyria Market by Diagnosis
10.4.6.2.2 Saudi Arabia Acute Intermittent Porphyria Market by Treatment
10.4.6.2.3 Saudi Arabia Acute Intermittent Porphyria Market by End-User
10.4.6.3 U.A.E Acute Intermittent Porphyria Market
10.4.6.3.1 U.A.E Acute Intermittent Porphyria Market by Diagnosis
10.4.6.3.2 U.A.E Acute Intermittent Porphyria Market by Treatment
10.4.6.3.3 U.A.E Acute Intermittent Porphyria Market by End-User
10.4.6.4 Rest of Middle East and Africa Acute Intermittent Porphyria Market
10.4.6.4.1 Rest of Middle East and Africa Acute Intermittent Porphyria Market by Diagnosis
10.4.6.4.2 Rest of Middle East and Africa Acute Intermittent Porphyria Market by Treatment
10.4.6.4.3 Rest of Middle East and Africa Acute Intermittent Porphyria Market by End-User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Acute Intermittent Porphyria Market Overview
10.5.2 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis
10.5.3 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis - By Diagnosis
10.5.4 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis - By Treatment
10.5.5 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis - By End-User
10.5.6 South and Central America Acute Intermittent Porphyria Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Acute Intermittent Porphyria Market
10.5.6.1.1 Brazil Acute Intermittent Porphyria Market by Diagnosis
10.5.6.1.2 Brazil Acute Intermittent Porphyria Market by Treatment
10.5.6.1.3 Brazil Acute Intermittent Porphyria Market by End-User
10.5.6.2 Argentina Acute Intermittent Porphyria Market
10.5.6.2.1 Argentina Acute Intermittent Porphyria Market by Diagnosis
10.5.6.2.2 Argentina Acute Intermittent Porphyria Market by Treatment
10.5.6.2.3 Argentina Acute Intermittent Porphyria Market by End-User
10.5.6.3 Rest of South and Central America Acute Intermittent Porphyria Market
10.5.6.3.1 Rest of South and Central America Acute Intermittent Porphyria Market by Diagnosis
10.5.6.3.2 Rest of South and Central America Acute Intermittent Porphyria Market by Treatment
10.5.6.3.3 Rest of South and Central America Acute Intermittent Porphyria Market by End-User
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ACUTE INTERMITTENT PORPHYRIA MARKET, KEY COMPANY PROFILES
13.1. RECORDATI RARE DISEASES INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. LUNDBECK INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. ALNYLAM PHARMACEUTICALS, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS

The List of Companies

1. Recordati Rare Diseases Inc.
2. Lundbeck Inc.
3. Alnylam Pharmaceuticals, Inc.

First Name *

Last Name

Country *

E-mail *

Contact No *

Company Name*

Job Title*

Comments

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Have a Question?

EMAIL US

RELATED PRODUCTS

ReportsWeb has an extensive coverage of industry reports, company reports and country reports accross all industries.

View All New Reports

Global In-Vitro Cancer Diagnostics Indus.. In-vitro cancer diagnostics is a technique in which the reag..

Global Lifting Agent for ESD & EMR Surge.. The Lifting Agent for ESD & EMR Surgery market revenue was..

Global Thoracic Surgery Industry Market .. The Thoracic Surgery market revenue was xx.xx Million USD ..

Global Homeopathic Remedies Industry Mar.. Homeopathy is a field of alternative medicine, introduced by..

Global Nigella Sativa Extract Industry M.. The Nigella Sativa Extract market revenue was xx.xx Millio..

Global Femoral Head Prostheses Industry .. The Femoral Head Prostheses market revenue was xx.xx Milli..

Global Canal Hearing Aid Industry Market.. The Canal Hearing Aid market revenue was xx.xx Million USD..

Global Dna Gel Imager Industry Market Re.. The Dna Gel Imager market revenue was xx.xx Million USD in..

Global Stress Ecg Industry Market Report.. The Stress Ecg market revenue was xx.xx Million USD in 201..

Global Total Organic Carbon Analyzers In.. The Total Organic Carbon (Toc) Analyzers market revenue wa..

Global Anti Rabies Vaccine Industry Mark.. Anti Rabies vaccine is a vaccine used to prevent rabies. The..

Global Orthopedics Devices Industry Mark.. The Orthopedics Devices market revenue was xx.xx Million U..

CUSTOM RESEARCH

ReportsWeb has an extensive coverage of industry reports, company reports and country reports accross all industries.

LEARN MORE